Skip to main content
Erschienen in: European Journal of Nutrition 2/2013

01.03.2013 | Original Contribution

LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia

verfasst von: Nicolas Ogier, Marie-Josèphe Amiot, Stéphane Georgé, Matthieu Maillot, Cécilia Mallmann, Marie Maraninchi, Sophie Morange, Jean-François Lescuyer, Sébastien L. Peltier, Nicolas Cardinault

Erschienen in: European Journal of Nutrition | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Red yeast rice (RYR), sugar cane-derived policosanols (SCdP) and artichoke leaf extracts (ALEs) are currently incorporated alone or in combination into dietary supplements for their potential low-density-lipoprotein cholesterol (LDL-cholesterol)-lowering effects. Yet, there is no information supporting the efficacy of this association on the reduction in LDL-cholesterol. The main objective of this study was to investigate the effects of a new dietary supplement (DS) with RYR, SCdP and ALEs on LDL-cholesterol.

Methods

In a double-blind, randomized, parallel controlled study, 39 subjects from 21 to 55 years with moderate hypercholesterolemia without drug treatment were assigned to 2 groups and then consumed either a DS containing RYR, SCdP and ALEs or a placebo over a 16-week period. Plasma concentrations of lipids [LDL-cholesterol, total cholesterol (TC), high-density-lipoprotein cholesterol (HDL-cholesterol), triacylglycerols (TG)] and plasma levels of vitamins C and E, total polyphenols and malondialdehyde were determined at baseline and after 4, 8, 12 and 16 weeks.

Results

LDL-cholesterol and TC were reduced by, respectively, 21.4 % (95 % CI, −13.3 to −24.9 %, p < 0.001) and 14.1 % (95 % CI, −10.1 to −18.0 %, p < 0.001) at week 16 in the DS group compared with baseline. Similar results were obtained at weeks 4, 8 and 12. TG decreased by 12.2 % after 16 weeks in the DS group (95 % CI: −24.4 to −0.1 %, p < 0.05). For the vitamin E/TC ratio, a difference was observed between groups at week 16 (p < 0.05). Other parameters were not modified.

Conclusions

Daily consumption of this new DS decreased LDL-cholesterol and TC and is therefore an interesting, convenient aid in managing mild to moderate hypercholesterolemia.
Literatur
1.
Zurück zum Zitat Wilson PW, Castelli WP, Kannel WB (1987) Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol 59:91G–94GCrossRef Wilson PW, Castelli WP, Kannel WB (1987) Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol 59:91G–94GCrossRef
2.
Zurück zum Zitat Robinson JG, Smith B, Maheshwari N, Schrott H (2005) Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 46:1855–1862CrossRef Robinson JG, Smith B, Maheshwari N, Schrott H (2005) Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 46:1855–1862CrossRef
3.
Zurück zum Zitat Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278CrossRef Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278CrossRef
4.
Zurück zum Zitat Vondrakova D, Ostadal P, Kruger A (2010) Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome. Lipids Health Dis 9:71CrossRef Vondrakova D, Ostadal P, Kruger A (2010) Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome. Lipids Health Dis 9:71CrossRef
5.
Zurück zum Zitat Kelly JP, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA (2005) Recent trends in use of herbal and other natural products. Arch Intern Med 165:281–286CrossRef Kelly JP, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA (2005) Recent trends in use of herbal and other natural products. Arch Intern Med 165:281–286CrossRef
6.
Zurück zum Zitat Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef
7.
Zurück zum Zitat Nijjar PS, Burke FM, Bloesch A, Rader DJ (2010) Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol 4:248–258CrossRef Nijjar PS, Burke FM, Bloesch A, Rader DJ (2010) Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol 4:248–258CrossRef
8.
Zurück zum Zitat Bogsrud MP, Ose L, Langslet G, Ottestad I, Strom EC, Hagve TA, Retterstol K (2010) HypoCol (red yeast rice) lowers plasma cholesterol: a randomized placebo controlled study. Scand Cardiovasc J 44:197–200CrossRef Bogsrud MP, Ose L, Langslet G, Ottestad I, Strom EC, Hagve TA, Retterstol K (2010) HypoCol (red yeast rice) lowers plasma cholesterol: a randomized placebo controlled study. Scand Cardiovasc J 44:197–200CrossRef
9.
Zurück zum Zitat Lin CC, Li TC, Lai MM (2005) Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol 153:679–686CrossRef Lin CC, Li TC, Lai MM (2005) Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol 153:679–686CrossRef
10.
Zurück zum Zitat Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL (1999) Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69:231–236 Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL (1999) Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69:231–236
11.
Zurück zum Zitat Huang CF, Li TC, Lin CC, Liu CS, Shih HC, Lai MM (2007) Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil 14:438–440CrossRef Huang CF, Li TC, Lin CC, Liu CS, Shih HC, Lai MM (2007) Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil 14:438–440CrossRef
12.
Zurück zum Zitat Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fonnebo V (2006) Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 1:4CrossRef Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fonnebo V (2006) Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 1:4CrossRef
13.
Zurück zum Zitat Heber D, Lembertas A, Lu QY, Bowerman S, Go VL (2001) An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 7:133–139CrossRef Heber D, Lembertas A, Lu QY, Bowerman S, Go VL (2001) An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 7:133–139CrossRef
14.
Zurück zum Zitat Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G (2005) Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 25:171–183CrossRef Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G (2005) Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 25:171–183CrossRef
15.
Zurück zum Zitat Gouni-Berthold I, Berthold HK (2002) Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 143:356–365CrossRef Gouni-Berthold I, Berthold HK (2002) Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 143:356–365CrossRef
16.
Zurück zum Zitat Wider B, Pittler MH, Thompson-Coon J, Ernst E (2009) Artichoke leaf extract for treating hypercholesterolaemia. Cochrane Database Syst Rev CD003335 Wider B, Pittler MH, Thompson-Coon J, Ernst E (2009) Artichoke leaf extract for treating hypercholesterolaemia. Cochrane Database Syst Rev CD003335
17.
Zurück zum Zitat Kaplan M, Aviram M (1999) Oxidized low density lipoprotein: atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med 37:777–787CrossRef Kaplan M, Aviram M (1999) Oxidized low density lipoprotein: atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med 37:777–787CrossRef
18.
Zurück zum Zitat Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, Suzuki T, Nagai R (2000) Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20:2243–2247CrossRef Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, Suzuki T, Nagai R (2000) Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20:2243–2247CrossRef
19.
Zurück zum Zitat Bowen PE, Borthakur G (2004) Postprandial lipid oxidation and cardiovascular disease risk. Curr Atheroscler Rep 6:477–484CrossRef Bowen PE, Borthakur G (2004) Postprandial lipid oxidation and cardiovascular disease risk. Curr Atheroscler Rep 6:477–484CrossRef
20.
Zurück zum Zitat Romero FJ, Bosch-Morell F, Romero MJ, Jareno EJ, Romero B, Marin N, Roma J (1998) Lipid peroxidation products and antioxidants in human disease. Environ Health Perspect 106(Suppl 5):1229–1234CrossRef Romero FJ, Bosch-Morell F, Romero MJ, Jareno EJ, Romero B, Marin N, Roma J (1998) Lipid peroxidation products and antioxidants in human disease. Environ Health Perspect 106(Suppl 5):1229–1234CrossRef
21.
Zurück zum Zitat Losonczy KG, Harris TB, Havlik RJ (1996) Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr 64:190–196 Losonczy KG, Harris TB, Havlik RJ (1996) Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr 64:190–196
22.
Zurück zum Zitat Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC (1993) Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328:1450–1456CrossRef Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC (1993) Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328:1450–1456CrossRef
23.
Zurück zum Zitat Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC (1993) Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 328:1444–1449CrossRef Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC (1993) Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 328:1444–1449CrossRef
24.
Zurück zum Zitat Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502 Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502
25.
Zurück zum Zitat Hu FB, Willett WC (2002) Optimal diets for prevention of coronary heart disease. JAMA 288:2569–2578CrossRef Hu FB, Willett WC (2002) Optimal diets for prevention of coronary heart disease. JAMA 288:2569–2578CrossRef
26.
Zurück zum Zitat Mente A, de Koning L, Shannon HS, Anand SS (2009) A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 169:659–669CrossRef Mente A, de Koning L, Shannon HS, Anand SS (2009) A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 169:659–669CrossRef
27.
Zurück zum Zitat Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Funck-Brentano C, Hasdai D, Hoes A, Kearney P, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Widimsky P, Windecker S, Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Lekakis J, Manolis AJ, Marques-Vidal P, Masana L, McMurray J, Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek ME, Zamorano JL (2011) ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:1769–1818CrossRef Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Funck-Brentano C, Hasdai D, Hoes A, Kearney P, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Widimsky P, Windecker S, Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Lekakis J, Manolis AJ, Marques-Vidal P, Masana L, McMurray J, Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek ME, Zamorano JL (2011) ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:1769–1818CrossRef
28.
Zurück zum Zitat Sirtori CR, Galli C, Anderson JW, Arnoldi A (2009) Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: focus on dietary proteins. Atherosclerosis 203:8–17CrossRef Sirtori CR, Galli C, Anderson JW, Arnoldi A (2009) Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: focus on dietary proteins. Atherosclerosis 203:8–17CrossRef
29.
Zurück zum Zitat Endo A (1979) Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo) 32:852–854CrossRef Endo A (1979) Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo) 32:852–854CrossRef
30.
Zurück zum Zitat Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ (2009) Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 150:830–839 Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ (2009) Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 150:830–839
31.
Zurück zum Zitat Journoud M, Jones PJ (2004) Red yeast rice: a new hypolipidemic drug. Life Sci 74:2675–2683CrossRef Journoud M, Jones PJ (2004) Red yeast rice: a new hypolipidemic drug. Life Sci 74:2675–2683CrossRef
32.
Zurück zum Zitat Guardamagna O, Abello F, Baracco V, Stasiowska B, Martino F (2011) The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis 21:424–429CrossRef Guardamagna O, Abello F, Baracco V, Stasiowska B, Martino F (2011) The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis 21:424–429CrossRef
33.
Zurück zum Zitat Reiner Z, Tedeschi-Reiner E, Romic Z (2005) Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients. Clin Drug Investig 25:701–707CrossRef Reiner Z, Tedeschi-Reiner E, Romic Z (2005) Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients. Clin Drug Investig 25:701–707CrossRef
34.
Zurück zum Zitat Castano G, Mas R, Fernandez L, Illnait J, Gamez R, Alvarez E (2001) Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Int J Clin Pharmacol Res 21:43–57 Castano G, Mas R, Fernandez L, Illnait J, Gamez R, Alvarez E (2001) Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Int J Clin Pharmacol Res 21:43–57
35.
Zurück zum Zitat Castano G, Fernandez L, Mas R, Illnait J, Mesa M, Fernandez JC (2003) Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clin Drug Investig 23:639–650CrossRef Castano G, Fernandez L, Mas R, Illnait J, Mesa M, Fernandez JC (2003) Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clin Drug Investig 23:639–650CrossRef
36.
Zurück zum Zitat Prat H, Roman O, Pino E (1999) Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia. Rev Med Chil 127:286–294 Prat H, Roman O, Pino E (1999) Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia. Rev Med Chil 127:286–294
37.
Zurück zum Zitat Singh DK, Li L, Porter TD (2006) Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther 318:1020–1026CrossRef Singh DK, Li L, Porter TD (2006) Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther 318:1020–1026CrossRef
38.
Zurück zum Zitat Marazzi G, Cacciotti L, Pelliccia F, Iaia L, Volterrani M, Caminiti G, Sposato B, Massaro R, Grieco F, Rosano G (2011) Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther 28:1105–1113CrossRef Marazzi G, Cacciotti L, Pelliccia F, Iaia L, Volterrani M, Caminiti G, Sposato B, Massaro R, Grieco F, Rosano G (2011) Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther 28:1105–1113CrossRef
39.
Zurück zum Zitat Francini-Pesenti F, Brocadello F, Beltramolli D, Nardi M, Caregaro L (2008) Sugar cane policosanol failed to lower plasma cholesterol in primitive, diet-resistant hypercholesterolaemia: a double blind, controlled study. Complement Ther Med 16:61–65CrossRef Francini-Pesenti F, Brocadello F, Beltramolli D, Nardi M, Caregaro L (2008) Sugar cane policosanol failed to lower plasma cholesterol in primitive, diet-resistant hypercholesterolaemia: a double blind, controlled study. Complement Ther Med 16:61–65CrossRef
40.
Zurück zum Zitat Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA, Weinberg GB (2006) Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial. Am Heart J 152(982):e981–e985 Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA, Weinberg GB (2006) Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial. Am Heart J 152(982):e981–e985
41.
Zurück zum Zitat Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I (2006) Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 295:2262–2269CrossRef Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I (2006) Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 295:2262–2269CrossRef
42.
Zurück zum Zitat Gebhardt R (1998) Inhibition of cholesterol biosynthesis in primary cultured rat hepatocytes by artichoke (Cynara scolymus L.) extracts. J Pharmacol Exp Ther 286:1122–1128 Gebhardt R (1998) Inhibition of cholesterol biosynthesis in primary cultured rat hepatocytes by artichoke (Cynara scolymus L.) extracts. J Pharmacol Exp Ther 286:1122–1128
43.
Zurück zum Zitat Bundy R, Walker AF, Middleton RW, Wallis C, Simpson HC (2008) Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomized, double blind placebo controlled trial. Phytomedicine 15:668–675CrossRef Bundy R, Walker AF, Middleton RW, Wallis C, Simpson HC (2008) Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomized, double blind placebo controlled trial. Phytomedicine 15:668–675CrossRef
44.
Zurück zum Zitat Englisch W, Beckers C, Unkauf M, Ruepp M, Zinserling V (2000) Efficacy of Artichoke dry extract in patients with hyperlipoproteinemia. Arzneimittelforschung 50:260–265 Englisch W, Beckers C, Unkauf M, Ruepp M, Zinserling V (2000) Efficacy of Artichoke dry extract in patients with hyperlipoproteinemia. Arzneimittelforschung 50:260–265
45.
Zurück zum Zitat Glass CK, Witztum JL (2001) Atherosclerosis. The road ahead. Cell 104:503–516CrossRef Glass CK, Witztum JL (2001) Atherosclerosis. The road ahead. Cell 104:503–516CrossRef
46.
Zurück zum Zitat Bazzano LA, Serdula MK, Liu S (2003) Dietary intake of fruits and vegetables and risk of cardiovascular disease. Curr Atheroscler Rep 5:492–499CrossRef Bazzano LA, Serdula MK, Liu S (2003) Dietary intake of fruits and vegetables and risk of cardiovascular disease. Curr Atheroscler Rep 5:492–499CrossRef
47.
Zurück zum Zitat Hung HC, Joshipura KJ, Jiang R, Hu FB, Hunter D, Smith-Warner SA, Colditz GA, Rosner B, Spiegelman D, Willett WC (2004) Fruit and vegetable intake and risk of major chronic disease. J Natl Cancer Inst 96:1577–1584CrossRef Hung HC, Joshipura KJ, Jiang R, Hu FB, Hunter D, Smith-Warner SA, Colditz GA, Rosner B, Spiegelman D, Willett WC (2004) Fruit and vegetable intake and risk of major chronic disease. J Natl Cancer Inst 96:1577–1584CrossRef
48.
Zurück zum Zitat French Study (2009) Etude individuelle nationale des consommations alimentation: INCA2, AFSSA French Study (2009) Etude individuelle nationale des consommations alimentation: INCA2, AFSSA
49.
Zurück zum Zitat Nagila A, Permpongpaiboon T, Tantrarongroj S, Porapakkham P, Chinwattana K, Deakin S, Porntadavity S (2009) Effect of atorvastatin on paraoxonase 1 (PON1) and oxidative status. Pharmacol Rep 61:892–898 Nagila A, Permpongpaiboon T, Tantrarongroj S, Porapakkham P, Chinwattana K, Deakin S, Porntadavity S (2009) Effect of atorvastatin on paraoxonase 1 (PON1) and oxidative status. Pharmacol Rep 61:892–898
50.
Zurück zum Zitat Meagher EA, Barry OP, Lawson JA, Rokach J, Fitzgerald GA (2001) Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 285:1178–1182CrossRef Meagher EA, Barry OP, Lawson JA, Rokach J, Fitzgerald GA (2001) Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 285:1178–1182CrossRef
Metadaten
Titel
LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia
verfasst von
Nicolas Ogier
Marie-Josèphe Amiot
Stéphane Georgé
Matthieu Maillot
Cécilia Mallmann
Marie Maraninchi
Sophie Morange
Jean-François Lescuyer
Sébastien L. Peltier
Nicolas Cardinault
Publikationsdatum
01.03.2013
Verlag
Springer-Verlag
Erschienen in
European Journal of Nutrition / Ausgabe 2/2013
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-012-0357-x

Weitere Artikel der Ausgabe 2/2013

European Journal of Nutrition 2/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.